Keyphrases
Prostate Carcinoma
100%
Oral Etoposide
100%
Hormone Refractory
100%
Estramustine
100%
VP16
75%
Median Survival
50%
Prostate-specific Antigen Level
50%
Survival Duration
50%
Prostate Cancer Cells
25%
Soft Tissue
25%
Disease Progression
25%
Prostate-specific Antigen
25%
Performance Status
25%
Hormone Therapy
25%
Tissue-specific Antigens
25%
Complete Response
25%
Partial Response
25%
Hormone-sensitive Prostate Cancer
25%
Etoposide
25%
Oral Regimen
25%
Off Therapy
25%
Survival Prediction
25%
Divided Dose
25%
Bone Scan
25%
Soft Tissue Disease
25%
Metastatic Prostate Carcinoma
25%
Pharmacology, Toxicology and Pharmaceutical Science
Etoposide
100%
Estramustine
100%
Adenocarcinoma
100%
Prostate Specific Antigen
75%
Endocrine Therapy
25%
Prostate Cancer
25%
Disease Exacerbation
25%
Prostate Carcinoma
25%
Castration Resistant Prostate Cancer
25%
Soft Tissue Disease
25%
Diseases
25%
Neuroscience
Etoposide
100%
Prostate
100%
Estramustine
100%
Prostate Specific Antigen
75%
Hormone Therapy
25%